PBAC's latest decision on Amino acid synthetic formula: Recommended with restriction (2015). Considered for Cows' milk protein enteropathy, severe cows' milk protein enteropathy with failure to thrive, combined intolerance to cows' milk protein/soy protein/protein hydrolysate formulae, proven combined IgE-mediated allergy to cows' milk protein and soy protein, cow's milk anaphylaxis, and severe intestinal malabsorption including short bowel syndrome in children aged 1 year and older.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Children aged 1 year and older with cows' milk protein enteropathy, severe cows' milk protein enteropathy with failure to thrive, combined intolerance to cows' milk protein/soy protein/protein hydrolysate formulae, proven combined IgE-mediated allergy to cows' milk protein and soy protein, cow's milk anaphylaxis, or severe intestinal malabsorption including short bowel syndrome.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Neocate Advance
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as submission was cost-minimisation based on equivalent price per gram of protein.